CASP3 and hepatocellular carcinoma: After 24 h of erlotinib treatment, neither cleavage of caspase-3 nor cleavage of PARP was observed in NIH-3T3 cells harboring L858R, T790M, EGFR WT, and all HCC-derived EGFR mutants (Fig. 7a).